ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Barry Simon sold 10,000 shares of the company's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $9.25, for a total transaction of $92,500.00. Following the transaction, the director directly owned 3,081,604 shares in the company, valued at $28,504,837. The trade was a 0.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
ImmunityBio Stock Performance
Shares of IBRX opened at $11.55 on Wednesday. The stock has a fifty day moving average of $4.82 and a two-hundred day moving average of $3.24. The company has a market capitalization of $11.38 billion, a PE ratio of -30.39 and a beta of 0.14. ImmunityBio, Inc. has a fifty-two week low of $1.83 and a fifty-two week high of $12.28.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, equities research analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.
More ImmunityBio News
Here are the key news stories impacting ImmunityBio this week:
Institutional Investors Weigh In On ImmunityBio
Large investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its holdings in shares of ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company's stock valued at $134,000 after acquiring an additional 29,297 shares in the last quarter. CWM LLC raised its position in ImmunityBio by 849.2% in the second quarter. CWM LLC now owns 48,715 shares of the company's stock valued at $129,000 after purchasing an additional 43,583 shares during the period. Dillon & Associates Inc. acquired a new position in shares of ImmunityBio during the second quarter worth about $68,000. Rathbones Group PLC boosted its position in shares of ImmunityBio by 21.5% in the second quarter. Rathbones Group PLC now owns 117,420 shares of the company's stock worth $310,000 after buying an additional 20,800 shares during the period. Finally, Summit X LLC purchased a new stake in shares of ImmunityBio in the second quarter worth about $28,000. Institutional investors and hedge funds own 8.58% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on IBRX. D. Boral Capital reiterated a "buy" rating and set a $23.00 price objective on shares of ImmunityBio in a report on Monday. Piper Sandler increased their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 20th. HC Wainwright lifted their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday. BTIG Research upped their price objective on ImmunityBio from $6.00 to $9.00 and gave the stock a "buy" rating in a report on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of ImmunityBio in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ImmunityBio has an average rating of "Moderate Buy" and an average target price of $12.60.
View Our Latest Stock Report on ImmunityBio
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
